Cargando…

Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials

The data report details the baseline characteristics and observed outcomes among patients included in a large US administrative claims database (Optum Labs Data Warehouse) and those enrolled in the pivotal phase III clinical trials examining apixaban, dabigratan, edoxaban and rivaroxaban versus warf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noseworthy, Peter A., Yao, Xiaoxi, Gersh, Bernard J., Hargraves, Ian, Shah, Nilay D., Montori, Victor M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Medicine and Dentistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568872/ https://www.ncbi.nlm.nih.gov/pubmed/28861455 http://dx.doi.org/10.1016/j.dib.2017.08.010

Ejemplares similares

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation
por: Giustozzi, Michela, et al.
Publicado: (2019)

Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation
por: Noseworthy, Peter A., et al.
Publicado: (2015)

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation
por: Noseworthy, Peter A., et al.
Publicado: (2022)

Oral anticoagulation following bioprosthetic SAVR in patients with atrial fibrillation: what’s the current status of NOACs?
por: Milojevic, Milan, et al.
Publicado: (2022)

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
por: de Veer, A. J. W. M., et al.
Publicado: (2019)

Cost Conversations About Anticoagulation Between Patients With Atrial Fibrillation and Their Clinicians: A Secondary Analysis of a Randomized Clinical Trial
por: Kamath, Celia C., et al.
Publicado: (2021)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation
Publicado: (2020)

Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial
por: Kunneman, Marleen, et al.
Publicado: (2017)

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
por: Pastori, Daniele, et al.
Publicado: (2018)

Clinical trial design data for electrocardiogram artificial intelligence-guided screening for low ejection fraction (EAGLE)
por: Yao, Xiaoxi, et al.
Publicado: (2019)

Contemporary trends and barriers to oral anticoagulation therapy in Non-valvular atrial fibrillation during DOAC predominant era
por: Sehrawat, Ojasav, et al.
Publicado: (2023)

Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges
por: Sabbag, Avi, et al.
Publicado: (2018)

Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism
por: Colonna, Paolo, et al.
Publicado: (2017)

New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
por: Rutherford, Ole-Christian Walter, et al.
Publicado: (2018)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
por: Melgaard, Line, et al.
Publicado: (2021)

Assessment of treatment patterns and patient awareness in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants (ASPECT-NOAC)
por: Badak, Özer, et al.
Publicado: (2022)

The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study
por: Grymonprez, M, et al.
Publicado: (2023)

Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016
por: Yao, Xiaoxi, et al.
Publicado: (2020)

Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?
por: Lin, Yi-Pin, et al.
Publicado: (2015)

Correction: New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
Publicado: (2020)

Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
por: Altman, Raul, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study
por: Paciaroni, Maurizio, et al.
Publicado: (2017)

Assessing Adherence and Persistence to Non-vitamin K Antagonist Oral Anticoagulants (NOACs) among Patients with Atrial Fibrillation in Tertiary-care Referral Centers in Malaysia
por: Kubas, Mohammed A, et al.
Publicado: (2020)

Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis
por: Caso, Valeria, et al.
Publicado: (2023)

Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs
por: Bielecka, Bernadetta, et al.
Publicado: (2022)

Post-TAVR patients with atrial fibrillation: are NOACs better than VKAs?—A meta-analysis
por: Wang, Lu, et al.
Publicado: (2023)

Is Atrial Fibrillation Management as Simple as ABC?
por: Yao, Xiaoxi, et al.
Publicado: (2020)

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
por: Kim, Hyeongsoo, et al.
Publicado: (2020)

Data for rate versus rhythm control strategy on stroke and mortality in patients with atrial fibrillation
por: Weng, Chi-Jen, et al.
Publicado: (2018)

Effect of Shared Decision‐Making for Stroke Prevention on Treatment Adherence and Safety Outcomes in Patients With Atrial Fibrillation: A Randomized Clinical Trial
por: Noseworthy, Peter A., et al.
Publicado: (2022)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Abstract 28. Novel Oral Anticoagulants (NOACs) in Microsurgery: A Review
por: Yao, Amy, et al.
Publicado: (2017)

Prognostic significance of patent foramen ovale in anticoagulated patients with atrial fibrillation
por: Melduni, Rowlens M, et al.
Publicado: (2020)

Initial experience with the convergent procedure for longstanding persistent atrial fibrillation: A 5 year dataset
por: Maclean, E., et al.
Publicado: (2020)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Data on prevalence of atrial fibrillation and its association with stroke in low-, middle-, and high-income regions of China
por: Wang, Xiaojun, et al.
Publicado: (2018)

The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey
por: Potpara, Tatjana S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5cn64a4bpm6hgqa3gf1q1mcrpl